XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Note 12 - Segment Information (Tables)
3 Months Ended
Jun. 30, 2023
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   

Three Months Ended June 30,

 
   

2023

   

2022

 

Revenues:

               

Sterilization and Disinfection Control

  $ 15,927     $ 14,774  

Clinical Genomics

    13,369       14,505  

Biopharmaceutical Development

    9,889       10,967  

Calibration Solutions

    11,460       10,207  

Total revenues (a)

  $ 50,645     $ 50,453  
                 

Gross profit:

               

Sterilization and Disinfection Control

  $ 11,591     $ 10,768  

Clinical Genomics

    6,728       7,849  

Biopharmaceutical Development

    6,433       7,077  

Calibration Solutions

    6,431       5,664  

Reportable segment gross profit

    31,183       31,358  

Corporate and Other (b)

    -       (17 )

Gross profit

  $ 31,183     $ 31,341  

Reconciling Items:

               

Operating expenses

    31,847       35,935  

Operating (loss)

    (664 )     (4,594 )

Nonoperating expense, net

    273       818  

(Loss) before income taxes

  $ (937 )   $ (5,412 )
Schedule of Segment Reporting Information, by Inventory Segment [Table Text Block]
   

June 30,

   

March 31,

 
   

2023

   

2023

 

Sterilization and Disinfection Control

  $ 3,758     $ 3,492  

Clinical Genomics

    13,744       13,985  

Biopharmaceutical Development

    8,889       8,384  

Calibration Solutions

    9,168       8,781  

Total inventories

  $ 35,559     $ 34,642